Gibson G J, Prescott R J, Muers M F, Middleton W G, Mitchell D N, Connolly C K, Harrison B D
Sarcoidosis Subcommittee of the Research Committee of the British Thoracic Society.
Thorax. 1996 Mar;51(3):238-47. doi: 10.1136/thx.51.3.238.
Corticosteroids suppress disease activity in pulmonary sarcoidosis and their use produces symptomatic, radiographic, and functional improvement. There is, however, uncertainty regarding their effects on the overall natural history of the condition and long term benefit is unproven.
Patients with pulmonary radiographic shadowing due to sarcoidosis were recruited in a multicentre study. Those who, in the first six months after entry to the study, neither required prednisolone for symptoms nor showed radiographic improvement were allocated at six months to receive either long term steroid treatment (group L) or selective treatment (group S), with regular assessment over the subsequent five years. Patients in group L were scheduled to receive steroid treatment for at least 18 months with the policy of achieving and maintaining maximal radiographic clearing, while in group S treatment was reserved for use only if warranted by later development of symptoms or deteriorating lung function. Symptoms, radiographic appearances, and respiratory function were assessed periodically during the study.
One hundred and forty nine patients were followed: 33 required prednisolone for troublesome symptoms within six months of entry and 58 showed radiographic improvement over this period. The remaining 58 patients were allocated to groups L (n = 27) and S (n = 31). Patients in group L showed greater improvements in symptoms, respiratory function, and radiographic appearances than those in group S, although the differences were not large. After adjusting for differences at the time of allocation, the average difference in vital capacity between groups L and S at final assessment was 9% of the predicted value. Side effects of treatment were frequent but usually mild, necessitating withdrawal in only two individuals.
After excluding those individuals who required steroids for control of symptoms, approximately half of the remaining patients with sarcoidosis and pulmonary shadowing showed spontaneous radiographic improvement during six months of observation. In those in whom the radiograph failed to improve, prolonged steroid treatment with the aim of optimising radiographic appearances resulted in a significantly better long term functional outcome.
皮质类固醇可抑制肺结节病的疾病活动,使用后可使症状、影像学表现及功能得到改善。然而,其对该病整体自然病程的影响尚不确定,长期获益也未得到证实。
在一项多中心研究中招募了因结节病出现肺部影像学阴影的患者。那些在进入研究后的前六个月既无需使用泼尼松龙控制症状,影像学也未改善的患者,在六个月时被分配接受长期类固醇治疗(L组)或选择性治疗(S组),并在随后五年内进行定期评估。L组患者计划接受至少18个月的类固醇治疗,目标是实现并维持最大程度的影像学病灶清除,而S组仅在后期出现症状或肺功能恶化时才进行治疗。在研究期间定期评估症状、影像学表现及呼吸功能。
共对149例患者进行了随访:33例在进入研究后的六个月内因症状困扰需要使用泼尼松龙,58例在此期间影像学表现有所改善。其余58例患者被分配至L组(n = 27)和S组(n = 31)。L组患者在症状、呼吸功能及影像学表现方面的改善程度均大于S组,尽管差异不大。在对分配时的差异进行调整后,最终评估时L组和S组之间肺活量的平均差异为预测值的9%。治疗的副作用很常见,但通常较轻,仅两名患者因副作用而停药。
在排除那些需要使用类固醇控制症状的患者后,其余约一半患有结节病且有肺部阴影的患者在六个月的观察期内影像学表现出现自发改善。对于那些影像学未改善的患者,以优化影像学表现为目标的长期类固醇治疗可带来显著更好的长期功能结局。